Search results
Past COVID infections may help protect against certain colds. Could it lead to better vaccines?
WPRI Providence· 6 days agoIf you’ve been sick with COVID-19, you may have some protection against certain versions of the...
COVID vaccine companies told to focus on KP.2 variant for fall shots, per FDA announcement
Fox News· 4 days agoThe U.S. Food and Drug Administration (FDA) has recommended thatCOVID vaccine manufacturers update...
A new Alzheimer's drug, combined COVID and flu vaccine update, and salmonella concerns. 3 health...
Yahoo Life Style via AOL· 4 days agoModerna's combo shot wins over separate ones Moderna’s latest medical innovation is packing a...
Moderna Just Gave Investors Another Reason to Buy the Stock
Motley Fool via Yahoo Finance· 3 days agoThis technology was unproven until 2020 (no mRNA-based vaccine had been approved or granted...
Summer COVID surge approaches in Seattle area as travel season begins
The Columbian· 2 days agoA summer COVID-19 surge is on its way through Seattle and the region. Infection rates and emergency...
COVID vaccine companies told to focus on KP.2 variant for fall shots, per FDA announcement
AOL· 4 days agoThe U.S. Food and Drug Administration (FDA) has recommended that COVID vaccine manufacturers update their formulas for fall doses, in ...
Past COVID infections may help protect against certain colds. Could it lead to better vaccines?
Dayton Daily News· 7 days agoIf you’ve been sick with COVID-19, you may have some protection against certain versions of the...
B.Riley lifts Vaxart shares target on BARDA award By Investing.com
Investing.com· 5 days agoThe award, which could total up to $453 million, is for conducting a Phase IIb study involving...
Moderna Just Gave Investors Another Reason to Buy the Stock
The Motley Fool via AOL· 3 days agoThis technology was unproven until 2020 (no mRNA-based vaccine had been approved or granted...
Moderna Announces Positive Phase 3 Efficacy Data for mRNA-1283, the Company’s Next Generation COVID-...
The Kansas City Star· 6 days agomRNA-1283 met its primary vaccine efficacy endpoint in a Phase 3 trial, demonstrating non-inferior vaccine efficacy against COVID-< ...